Casodex Prostatic Carcinoma

Stop seeking.You have found!
AstraZeneca Clinical Trials
To compare escalating doses of CASODEX (300 mg po daily, increasing by 150 mg dose for efficacy, in the treatment of M0 or M1 prostate carcinoma.
www.astrazenecaclinicaltrials.com/article/514306.aspx
Prostate Cancer and Prostatic Diseases - Bicalutamide vs
Prostate carcinoma presentation, diagnosis and staging: an update from the National of the new non-steroidal anti-androgen Casodex in prostate cancer.
www.nature.com/pcan/journal/v8/n1/full/4500784a.html
The Journal of Urology : Case Reports: Withdrawal Phenomenon With
4 G.T. Kennealey and B.J. Furr, Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma, Urol. Clin. N. Amer. 18 (1991), p. 99.
linkinghub.elsevier.com/retrieve/pii/S0022534701676444
Prostate Cancer Info : education, support, male hormone therapy
CASODEX 50 mg daily is indicated for use in combination therapy with a luteinizing with advanced prostatic carcinoma: final report of a double-blind.
www.prostateinfo.com/professionals/casodex/index.asp
Diethylstilboestrol versus bicalutamide in hormone refractory
In hormone refractory prostate carcinoma: A prospective randomised trial. ‘Casodex’) in patients with hormone refractory prostate cancer (HRPC).
www.casodex.net/13377_19337_10__.aspx
The Journal of Urology : Bicalutamide in the Treatment of Advanced
1 G.T. Kennealey and B.J. Furr, Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma., Urol. Clin. N. Amer. 18 (1991), p. 99.
linkinghub.elsevier.com/retrieve/pii/S0022534701667090
Bicalutamide
Kennealey GT and Furr BJ, "Use of the Nonsteroidal Antiandrogen Casodex in Advanced Prostatic Carcinoma," Urol Clin North Am , 1991, 18(1):99-110.
www.umm.edu/altmed/drugs/bicalutamide-015550.htm
Antagonist/Agonist Balance of the Nonsteroidal Antiandrogen
Androgen ablation is standard therapy for advanced prostate carcinoma. was stimulated by the pure nonsteroidal antiandrogen bicalutamide (Casodex).
content.karger.com/ProdukteDB/
[Monitoring of erection function in patients with prostatic
Function in patients with prostatic carcinoma treated with Casodex] advanced prostate cancer (T3NOMO) during 6 months treatment with Casodex by.
www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&
Efficacy - Casodex 50 mg vs Flutamide
Casodex’ plus LHRHa is at least as effective as flutamide plus LHRHa in terms of with advanced prostatic carcinoma: final report of a double-blind.
www.casodex.net/9958_10045_7_2_3.aspx